Showing 1 - 6 results of 6 for search 'Chong‐Sheng Qian', query time: 0.03s Refine Results
  1. 1
    MYC-regulated lncRNA NEAT1 promotes B cell proliferation and lymphomagenesis via the miR-34b-5p-GLI1 pathway in diffuse large B-cell lymphoma

    MYC-regulated lncRNA NEAT1 promotes B cell proliferation and lymphomagenesis via the miR-34b-5p-GLI1 pathway in diffuse large B-cell lymphoma by Chong-Sheng Qian, Ling-Jie Li, Hai-Wen Huang, Hai-Fei Yang, De-Pei Wu

    Published 2020-03-01
    Get full text
    Article
  2. 2
    Patients with CML in the lymphoid blastic phase have inferior response to anti‐CD19 CAR T‐cell therapy compared to de novo Ph‐positive B cell acute lymphoblastic leukemia

    Patients with CML in the lymphoid blastic phase have inferior response to anti‐CD19 CAR T‐cell therapy compared to de novo Ph‐positive B cell acute lymphoblastic leukemia by Mei‐Jing Liu, Kai‐Wen Tan, Han‐Yu Cao, Si‐Man Huang, Chong‐Sheng Qian, Sheng‐Li Xue, Hai‐Ping Dai, Wen‐Jie Gong

    Published 2024-02-01
    Get full text
    Article
  3. 3
    Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration

    Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration by Han-Yu Cao, Han-Yu Cao, Hui Chen, Song-Bai Liu, Wen-Jie Gong, Wen-Jie Gong, Chong-Sheng Qian, Chong-Sheng Qian, Tong-Tong Zhang, Tong-Tong Zhang, Chao-Ling Wan, Chao-Ling Wan, Si-Man Huang, Si-Man Huang, Nan Xu, Hai-Ping Dai, Hai-Ping Dai, Sheng-Li Xue, Sheng-Li Xue

    Published 2023-04-01
    Get full text
    Article
  4. 4
    Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy

    Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy by Si‐Man Huang, Chao‐Ling Wan, Han‐Yu Cao, Yan‐Yan Li, Chong‐Sheng Qian, Hai‐Xia Zhou, Ming‐Zhu Xu, Xiao‐Hui Hu, Lan Dai, Hai‐Ping Dai, Sheng‐Li Xue

    Published 2023-12-01
    Get full text
    Article
  5. 5
    Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL

    Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL by Yan Qiu, Chao-Ling Wan, Ming-Zhu Xu, Hai-Xia Zhou, Mei-Jing Liu, Wen-Jie Gong, Li-Qing Kang, Ai-Ning Sun, Lei Yu, De-Pei Wu, Chong-Sheng Qian, Sheng-Li Xue

    Published 2023-05-01
    Get full text
    Article
  6. 6
    A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia

    A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia by Jia Yin, Jia Yin, Chao-Ling Wan, Chao-Ling Wan, Ling Zhang, Ling Zhang, Hao Zhang, Lian Bai, Hai-Xia Zhou, Hai-Xia Zhou, Ming-Zhu Xu, Ming-Zhu Xu, Li-Yun Chen, Li-Yun Chen, Chong-Sheng Qian, Chong-Sheng Qian, Hui-Ying Qiu, Hui-Ying Qiu, Su-Ning Chen, Su-Ning Chen, Xiao-Wen Tang, Xiao-Wen Tang, De-Pei Wu, De-Pei Wu, Yan-Ming Zhang, Ai-Ning Sun, Ai-Ning Sun, Sheng-Li Xue, Sheng-Li Xue

    Published 2021-09-01
    Get full text
    Article

Search Tools: